GET DAILY SIGNALSAuna (AUC): Analyst Mean Target of $7 Suggests +56% Potential Upside
Key Takeaways
- The central target discussed here is $7, which reflects the arithmetic mean of the verified analyst price targets reviewed for Auna (AUC), not a single firm's view.
- With the shares trading near $4.50, reaching $7 would require a gain of roughly 56%, a substantial move from current levels.
- The analyst price target range is wide, from about $5 to $9, signaling genuine disagreement about the company's growth and balance-sheet trajectory.
- The strongest supporting factors are a deeply discounted valuation and improving sell-side sentiment, including a recent HSBC upgrade and a Jefferies Buy initiation.
- The biggest risks are a slower-than-expected ramp-up in Mexico, elevated leverage, and earnings that have repeatedly missed expectations.
- For more detail, explore Auna's Major News and Today's Price Move, review the Forecast, and track upcoming Earnings.
- Readers can also explore Trending AI Robots to see how AI-driven trading strategies are positioning across the market.
Analyst Price Targets and Consensus View
Auna S.A. (AUC) is a Luxembourg-based healthcare provider operating hospitals, clinics, prepaid healthcare, and oncology plans across Mexico, Peru, and Colombia. Analyst coverage is modest but active: roughly seven sell-side targets were reviewed, spanning a low of about $5.00 to a high of about $9.00, with the mean of those targets landing near $6.99, which rounds to a central target of $7.
Views are split rather than uniform. JPMorgan analyst Joseph Giordano holds a Neutral rating and cut the target to $5 in May 2026, citing a slower Mexico ramp-up and sustained leverage. In contrast, Jefferies initiated coverage with a Buy and a $9 target in January 2026, and HSBC upgraded the stock to Buy near the same time with a roughly $6.90 target. BTG Pactual set a $7 target in February 2026. An earlier Morgan Stanley target near $10 appears to have since been revised lower or grown stale. The wide $5-to-$9 range reflects a genuine debate over how quickly the company can scale while managing its debt load. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
The stock trades near $4.50, toward the lower end of a 52-week range of roughly $4.09 to $6.29. Reaching $7 implies upside of about 56% — a substantial move that would require not just a re-rating but a meaningful recovery in earnings expectations. The company reports revenue growth in the low double digits, but profitability remains thin, with a trailing P/E around 75 and a far lower forward multiple, reflecting hopes that earnings normalize as operations mature. A path toward $7 would likely depend on better-than-expected execution in Mexico, margin expansion, and deleveraging, which would justify a higher multiple.
What Could Support a Move Toward the Target
- A deeply discounted valuation, with the stock trading at a low-single-digit forward P/E and a low price-to-free-cash-flow multiple, gives room for upside if fundamentals stabilize.
- Recent constructive research, including a Jefferies Buy initiation and an HSBC upgrade, suggests some analysts see the risk-reward as improving.
- Low-teens revenue growth and a large levered free cash flow base (roughly $315 million) provide a foundation for reinvestment and deleveraging.
- The company affirmed its full-year 2026 sales outlook, offering some visibility on the revenue trajectory.
What Could Prevent the Target From Being Reached
- Earnings have repeatedly disappointed; the most recent quarterly EPS missed consensus by a wide margin and declined sharply year over year.
- Elevated leverage, with a debt-to-equity ratio near 185%, constrains financial flexibility and weighs on analyst assumptions about the required discount rate.
- A slower-than-expected ramp-up in Mexico has prompted multiple target cuts over the past year, and execution risk remains central to the bear case.
- Thin profitability (low single-digit return on equity) means the valuation multiple could remain compressed if margins do not improve.
Technical Levels and Market Structure
Technically, the shares sit below both the 50-day and 200-day moving averages, which cluster in the $5.10-to-$5.20 area — an overhead resistance zone that the stock would first need to reclaim. Above that, the 52-week high near $6.29 marks a more significant resistance level before any test of $7. On the downside, the 52-week low near $4.09 and the current $4.50 area represent nearby support. The stock has shown signs of being oversold, but a durable recovery would likely require clearing the $5.20 zone to shift the longer-term trend structure.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual analysts may use different assumptions. Investors should watch the next earnings report for confirmation or revision of guidance, particularly on Mexico performance, margins, and any progress on debt reduction. Additional items to monitor include analyst revisions, currency and macroeconomic conditions across Mexico, Peru, and Colombia, and any regulatory or competitive developments in the regional healthcare market.
Exploring Tickeron’s AI Daily Buy/Sell Signals
In my own research process, I find Tickeron’s AI Daily Buy/Sell Signals helpful for monitoring names like Auna alongside broader market trends. These tools apply artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on technical behavior and shifting conditions. They can surface opportunities or highlight momentum changes without requiring constant manual review, which is useful when following healthcare names with evolving fundamentals.
Final Assessment
The $7 central target for Auna (AUC) is the mean of a wide and genuinely divided set of analyst views, not a consensus guarantee. It implies a roughly 56% advance from the current price — a substantial move that hinges on improved execution, margin expansion, and a more comfortable balance sheet. The bull case rests on a cheap valuation and increasingly constructive research, while the bear case centers on persistent earnings misses, high leverage, and a slower Mexico ramp-up. Whether the shares can approach $7 will depend largely on whether upcoming results show the operational trajectory finally turning, making earnings and guidance the key variables to watch rather than the headline target itself.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AUC in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 30, 2026
AUC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 44 of 48 cases where AUC's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +2.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where AUC advanced for three days, in 155 of 196 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Aroon Indicator entered an Uptrend today. In 65 of 79 cases where AUC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 53 cases where AUC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on October 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AUC as a result. In 128 of 134 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for AUC turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 50 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
AUC moved below its 50-day moving average on October 28, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AUC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. AUC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 75 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AUC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.094) is normal, around the industry mean (3.059). P/E Ratio (-0.917) is within average values for comparable stocks, (6.833). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (0.809). Dividend Yield (0.000) settles around the average of (8.748) among similar stocks. P/S Ratio (10.799) is also within normal values, averaging (16.899).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a holding and consulting company, which provides financial consulting services
Industry InvestmentBanksBrokers
Advertisement